Expression of cyclooxygenase-2, glucose transporter-1 and angiogenesis in gallbladder carcinomas and their impact on prognosis

Legan, Mateja; Luzar, Boštjan; Marolt, Vera Ferlan

doi:10.1080/00365520903121685

Cited by 13 publications

(12 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All of the included studies measured the expression of GLUT1 by means of immunohistochemistry (IHC) staining or PCR in human tissues, and the cut-off values varied across studies. Among the studies, 4 evaluated lung cancer [5–8], 3 evaluated pancreatic cancer [9–11], 3 evaluated breast cancer [12, 14], 2 evaluated gallbladder cancer [10, 15], 2 evaluated gastric cancer [16, 17], 2 evaluated colorectal cancer [18, 19], 2 evaluated laryngeal cancer [20, 21], and 1 each evaluated hypopharyngeal cancer [22], endometrial cancer [23], salivary gland tumor [24], adrenocortical cancer [25], liver cancer [26], ampulla of Vater cancer [10], extrahepatic bile duct cancer [10], oral cancer [27], neuroblastic tumors [28], cervical cancer [29], ovarian cancer [30] and esophageal cancer [31]. Due to the retrospective design of the included studies, only five studies examined both OS and DFS [6, 12, 14, 25, 29].…”

Section: Resultsmentioning

confidence: 99%

“…Due to the retrospective design of the included studies, only five studies examined both OS and DFS [6, 12, 14, 25, 29]. Sixteen studies investigated the association between GLUT1 level and OS [7–11, 15–21, 24, 27, 28, 30], while four studies investigated the association between GLUT1 and DFS [5, 13, 23, 26]. Studies by Mineta [22] reported relapse-free survival data, whereas study by Sawayama [31] reported data of relapse-free survival and cancer-specific survival.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis

et al. 2017

View full text Add to dashboard Cite

Increased glycolysis is one of the hallmarks of cancer. The abnormal expression of glucose transporter 1 (GLUT1) was reported to be associated with resistance to current therapy and poor prognosis. Numerous studies have investigated the correlation between GLUT1 expression and prognosis in cancers, but the conclusions are still controversial. Here, we conducted a meta-analysis to explore the association between GLUT1 and survival in human cancers. PubMed, Springer, Medline, and Cochrane Library were searched carefully to identify eligible studies evaluating prognostic value of GLUT1 in cancers. Twenty-seven studies with 4079 patients were included in the present study. Our pooled results identified that increased expression of GLUT1 was associated with unfavorable overall survival (HR = 1.780, 95% CI = 1.574–.013, p < 0.001)) and poorer disease-free survival (HR = 1.95, 95% CI = 1.229–3.095, p = 0.003). Furthermore, overexpression of GLUT1 linked with poor differentiated tumors (RR = 1.380, 95% CI = 1.086–1.755, p = 0.009; I2 = 72.0%, p < 0.001), positive lymph node metastasis (RR = 1.395, 95% CI = 1.082–1.799, p = 0.010; I2 = 70.8%, p = 0.002) and larger tumor size (RR = 1.405, 95% CI = 1.231–1.603, p < 0.001; I2 = 37.3%, p = 0.093). This systematic review and meta-analysis indicated that the GLUT1 may serve as an ideal prognostic biomarker in various cancers.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In fact, Glut-1 expression has been associated with a poor prognosis in gallbladder cancer [19], oral SC [20], SC of the tongue [21], pancreatic cancer [22], and soft tissue sarcoma [23], and the association between HIF1α and poor prognosis has been reported in breast cancer [24][25][26], nonsmall cell lung cancer [27], nasopharyngeal carcinoma [28], esophageal SC [29], and laryngeal SC [30]. In addition, COX2 expression has been associated with a poor prognosis in laryngeal SC [30] and nasopharyngeal carcinoma [28].…”

Section: Discussionmentioning

confidence: 99%

Hypoxia-related protein expression and its clinicopathologic implication in carcinoma of unknown primary

Koo

Kim

2011

Tumor Biol.

View full text Add to dashboard Cite

Carcinoma of unknown primary (CUP) is a heterogeneous entity with different clinical and histological features. The aim of this study was to investigate the clinicopathological features and expression of proteins associated with carcinogenesis and tumor environment in different histological subtypes of CUP. Sixty-nine cases of CUP were subjected to immunohistochemistry for EGFR, phospho-EGFR, HER-2, phospho-HER-2, p53, ERCC1, RRM1, REDD1, HIF1α, COX-2, GLUT-1, 14-3-3σ, Phospho-mTOR, Phospho-S6, AMPKα1, Phospho-Akt, PDGF-β receptor, and caveolin-1, and fluorescence in situ hybridization for HER-2 gene amplification. Fourteen (20.3%) cases were poorly differentiated carcinoma, 24 (34.8%) were adenocarcinoma (AD), 17 (24.6%) were squamous cell carcinoma (SC), and 14 (20.3%) were undifferentiated carcinoma (UD). AD were mostly carcinomatosis type, while SC and UD were mostly nodal type (p < 0.001). SC showed more frequent EGFR overexpression (p < 0.001) and Glut-1 (p = 0.001). AD (p = 0.001) and carcinomatosis (p < 0.001) types showed shorter overall survival. SCs expressing Glut-1, HIF1α, and COX2 showed a poor prognosis (p = 0.048, 0.029, and 0.042, respectively). CUP shows various clinicopathological features according to the histological subtypes. SC is mainly associated with nodal metastasis in the head and neck, and frequent EGFR overexpression and Glut-1 expression. Glut-1, HIF1α, and COX2 expression in SC is associated with a poor prognosis.

show abstract

“…Patients with tumors that showed strong GLUT-1 expression had a significantly shorter survival time than GLUT-1 Immunoreactivity of the Gallbladder patients whose tumors showed negative, weak or moderate GLUT-1 expression (6.3±7.0 months vs. 17.7±22.4 months, p<0.001) [19].…”

Section: Resultsmentioning

confidence: 99%

Glucose Transporter-1 (GLUT-1) Immunoreactivity in Benign, Premalignant and Malignant Lesions of the Gallbladder

Legan

Tevžič

Tolar

et al. 2010

Pathol. Oncol. Res.

Self Cite

View full text Add to dashboard Cite

GLUT-1 is a transmembrane glucose transport protein that allows the facilitated transport of glucose into cells, normally expressed in tissues which depend mainly on glucose metabolism. Enhanced expression of GLUT-1 can also be found in a large spectrum of carcinomas. This study aimed to investigate GLUT-1 expression in gallbladder tissue: from normal tissue samples, hyperplasias, low-grade and high-grade dysplasias to gallbladder carcinomas. In all, 115 archived samples of gallbladder tissue from 68 patients, presented after cholecystectomy, were immunohistochemically stained for GLUT-1. According to the intensity of GLUT-1 immunoreactivity, samples were divided into negative (stained 0-10% of cells stained), positive with weak to moderate (10-50%) and positive with strong (>50%) GLUT-1 expression. The GLUT-1 immunoreactivity of the samples showed a characteristic increase from premalignant lesions to carcinomas. Normal gallbladder tissue samples did not express GLUT-1 (100%). Weak expression was shown only focally in hyperplasias, but to a greater extent with low-grade dysplasias (20%), high-grade dysplasias (40%) and carcinomas (51.8%). Normal gallbladder tissue is GLUT-1 negative. GLUT-1 expression in carcinoma tissue is significantly higher than in dysplastic lesions. Strong GLUT-1 expression indicates 100% specificity for detecting gallbladder carcinomas. Therefore, GLUT-1 is a candidate as a diagnostic as well as a tissue prognostic marker in gallbladder carcinoma patients.

show abstract

Expression of cyclooxygenase-2, glucose transporter-1 and angiogenesis in gallbladder carcinomas and their impact on prognosis

Abstract: Next to age and gender of patients, hypoxia of gallbladder tumours is a factor influencing survival. Among hypoxic factors, GLUT-1 expression is an important (significant) denominator of poor prognosis in gallbladder carcinomas, but not COX-2 nor angiogenesis.

Cited by 13 publications

References 32 publications

The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis

The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis

Hypoxia-related protein expression and its clinicopathologic implication in carcinoma of unknown primary

Glucose Transporter-1 (GLUT-1) Immunoreactivity in Benign, Premalignant and Malignant Lesions of the Gallbladder

Contact Info

Product

Resources

About